Clarke B. Futch
InvestorChairman and Chief Executive Officer at HEALTHCARE ROYALTY PARTNERS
About
Clarke B. Futch is Chairman and CEO of HCRx, where he sets the firm's strategic direction and evaluates new opportunities. Since 2001 he has led or co-led over 100 royalty-related acquisitions and has over 30 years of experience in biopharmaceutical and healthcare investing and financing. He previously was a partner at Paul Capital Partners, a founding member of the healthcare group at Thomas Weisel Partners (now Stifel), and a vice president at Raymond James. He holds a BA from Vanderbilt University and a JD from the University of Virginia School of Law.
Invests in
Biotech
Colleagues at HEALTHCARE ROYALTY PARTNERS
Aaron B. Simon
Associate at HEALTHCARE ROYALTY PARTNERS
Amy J. Zacharias
Senior Vice President and Controller at HEALTHCARE ROYALTY PARTNERS
Andrew Logerfo
Vice President at HEALTHCARE ROYALTY PARTNERS
Carlos M. Almodóvar
Chief Business Officer at HEALTHCARE ROYALTY PARTNERS
Christopher A. White
President and Chief Financial Officer at HEALTHCARE ROYALTY PARTNERS
David Oron
Analyst at HEALTHCARE ROYALTY PARTNERS
Eric Yoo
Vice President, PharmD at HEALTHCARE ROYALTY PARTNERS
Evan Bograd
Vice President at HEALTHCARE ROYALTY PARTNERS
Frequently asked questions
- Who is Clarke B. Futch?
- Clarke B. Futch is Chairman and CEO of HCRx, where he sets the firm's strategic direction and evaluates new opportunities. Since 2001 he has led or co-led over 100 royalty-related acquisitions and has over 30 years of experience in biopharmaceutical and healthcare investing and financing. He previously was a partner at Paul Capital Partners, a founding member of the healthcare group at Thomas Weisel Partners (now Stifel), and a vice president at Raymond James. He holds a BA from Vanderbilt University and a JD from the University of Virginia School of Law.
- Where does Clarke B. Futch work?
- Clarke B. Futch is Chairman and Chief Executive Officer at HEALTHCARE ROYALTY PARTNERS.
- What does Clarke B. Futch invest in?
- Clarke B. Futch invests in Biotech.








